Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | ARAF | P10398 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575944 | 1.00 | RORC (0.34) | RORCBRAFKDRADORA2BADORA1 | |
| SCHEMBL21298664 | 0.85 | KDR (0.39) | RORCBRAFKDRADORA2BADORA1 | |
| SCHEMBL20576567 | 0.85 | ADORA2B (0.33) | ADORA2BADORA1 | |
| SCHEMBL20576569 | 0.85 | ADORA2B (0.33) | ADORA2BADORA1 | |
| SCHEMBL20576583 | 0.84 | CSNK1D (0.33) | ADORA2BADORA1CACNA1H | |
| SCHEMBL20576581 | 0.84 | CSNK1D (0.33) | ADORA2BADORA1CACNA1H | |
| SCHEMBL20576699 | 0.82 | ABL1 (0.33) | ADORA2BADORA1ABL1SYK | |
| SCHEMBL20576698 | 0.82 | ABL1 (0.33) | ADORA2BADORA1ABL1SYK | |
| SCHEMBL20576260 | 0.81 | BRAF (0.31) | BRAFKDRABL1 | |
| SCHEMBL20576257 | 0.81 | BRAF (0.31) | BRAFKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392367-B2 | IRE1 small molecule inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180346447-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392367-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | RORC 3226/4885BRAF 1396/4885KDR 3965/4885 |
| US-20180346447-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | RORC 3226/4885BRAF 1396/4885KDR 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.